[go: up one dir, main page]

ES2094113T3 - Dna que codifica cd40. - Google Patents

Dna que codifica cd40.

Info

Publication number
ES2094113T3
ES2094113T3 ES89103127T ES89103127T ES2094113T3 ES 2094113 T3 ES2094113 T3 ES 2094113T3 ES 89103127 T ES89103127 T ES 89103127T ES 89103127 T ES89103127 T ES 89103127T ES 2094113 T3 ES2094113 T3 ES 2094113T3
Authority
ES
Spain
Prior art keywords
dna coding
cdna
image
host cell
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89103127T
Other languages
English (en)
Inventor
Brian Dr Seed
Janet Allen
Alejandro Aruffo
David Camerini
Leander Dr Lauffer
Carmen Patricia Oquendo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2094113T3 publication Critical patent/ES2094113T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

UN SIMPLE Y ALTAMENTE EFICIENTE METODO PARA CLONAR CDNA3 DE RESERVAS DE EXPRESION MAMIFERA BASADO EN LA EXPRESION TRANSITORIA EN LAS CELULAS HUESPED DE LOS MAMIFEROS, HA SIDO DESCUBIERTO. SE HA REVELADO UNA NUEVA EXPRESION DE LOS VECTORES QUE PERMITESN LA CONSTRUCCION ALTAMENTE EFICIENTE DE RESERVAS DE CDNA MAMIFERO. EL METODO DE CLONAJE DE LA INVENCION, EL CUAL HA SIDO UTILIZADO PARA CLONAR GENES POR LOS ANTIGENOS DE LA SUPERFICIE DE LA CELULA DE ANTIGENOS HUMANOS, TIENE UNA APLICACION GENERAL EN EL CLONAJE DE GENES. LOS ANTIGENOS DE LA SUPERFICIE DE LA CELULA CLONADOS DE ACUERDO A LA PRESENTE INVENCION HAN SIDO PURIFICADOS, Y EL NUCLEOTIDO Y LAS SECUENCIAS DE AMINOACIDOS HAN SIDO DETERMINADOS. ESTOS ANTIGENOS TIENEN DIAGNOSTICO Y UTILIDAD TERPEUTICA EN INFECCIONES INMUNOINTERMEDIAS EN MAMIFEROS, INCLUYENDO HUMANOS.
ES89103127T 1988-02-25 1989-02-23 Dna que codifica cd40. Expired - Lifetime ES2094113T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16041688A 1988-02-25 1988-02-25

Publications (1)

Publication Number Publication Date
ES2094113T3 true ES2094113T3 (es) 1997-01-16

Family

ID=22576817

Family Applications (2)

Application Number Title Priority Date Filing Date
ES89103127T Expired - Lifetime ES2094113T3 (es) 1988-02-25 1989-02-23 Dna que codifica cd40.
ES96104493T Expired - Lifetime ES2164794T3 (es) 1988-02-25 1989-02-23 Dna que codifica cd 19.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96104493T Expired - Lifetime ES2164794T3 (es) 1988-02-25 1989-02-23 Dna que codifica cd 19.

Country Status (6)

Country Link
EP (2) EP0739980B1 (es)
AT (2) ATE143690T1 (es)
DE (2) DE68927277T2 (es)
ES (2) ES2094113T3 (es)
HU (1) HUT53672A (es)
WO (1) WO1989008114A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767077A (en) * 1988-05-27 1998-06-16 Applied Research Systems Ars Holding N.V. Human Fc-γ receptor III
ATE321134T1 (de) * 1988-05-27 2006-04-15 Applied Research Systems Menschlicher fc-gamma-rezeptor iii
EP0387668B1 (en) * 1989-03-09 1996-12-11 Center For Blood Research, Inc. Intercellular adhesion molecule - 2 and its binding ligands
EP0417563B1 (de) * 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5264554A (en) * 1990-01-19 1993-11-23 The Blood Center Of Southeastern Wisconsin, Inc. Platelet cell adhesion molecule and variants thereof
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5622853A (en) * 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
CS156891A3 (en) * 1990-06-01 1992-04-15 Regeneron Pharma Receptor of a cilary neurotropic factor
KR100206524B1 (ko) * 1990-07-13 1999-07-01 어니스트 엠. 해데드 씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
US6071716A (en) * 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
US6238875B1 (en) * 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
DE69233441T2 (de) * 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Menschliches Zelloberflächen-Antigen codierende DNA
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
AU6123894A (en) * 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
WO1995006750A1 (en) * 1993-09-03 1995-03-09 Cellpro, Incorporated Methods for quantifying the number of cells containing a selected nucleic acid sequence in a heterogenous population of cells
IL111748A0 (en) * 1993-12-03 1995-01-24 Zeneca Ltd Proteins
GB9404513D0 (en) * 1994-03-09 1994-04-20 Medical Res Council Method of cloning
US5587299A (en) * 1994-04-20 1996-12-24 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof
US5817516A (en) 1994-04-28 1998-10-06 Boehringer Ingelheim Pharmaceuticals, Inc. Methods for proliferating and differentiating B cells with high density membrane CD40 ligand
US5925557A (en) * 1994-09-29 1999-07-20 The Regents Of The University Of California DNA encoding mitogen activated protein kinase, FRK
WO1996040726A1 (en) 1995-06-07 1996-12-19 Genta Incorporated Novel carbamate-based cationic lipids
AU4825699A (en) * 1998-06-19 2000-01-05 Genzyme Corporation Identification and use of differentially expressed genes and polynucleotide sequences
NZ514914A (en) 1999-05-07 2004-09-24 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
CA2393126C (en) * 1999-11-29 2016-05-24 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
US7067252B2 (en) 2000-06-21 2006-06-27 Novozymes A/S Method for genome mining for secreted protein genes
AU2001265836A1 (en) * 2000-06-21 2002-01-02 Novozymes A/S Method for genome mining for secreted protein genes
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
ES2322267T3 (es) 2003-04-09 2009-06-18 Genentech, Inc. Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
CA2526402A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
US20080299546A1 (en) * 2004-02-10 2008-12-04 Nihon University Canine Cd20 Gene
MXPA06014069A (es) 2004-06-04 2007-04-25 Genentech Inc Metodo para tratar esclerosis multiple.
CN102397542B (zh) 2004-11-18 2014-05-07 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
EP3153525A1 (en) 2005-03-23 2017-04-12 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
KR20080046135A (ko) 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
CA2616395C (en) 2005-07-25 2016-10-04 Trubion Pharmaceuticals B-cell reduction using cd37-specific and cd20-specific binding molecules
EP1919505A2 (en) 2005-07-25 2008-05-14 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
US9040050B2 (en) 2006-09-26 2015-05-26 Genmab A/S Combination treatment of CD38-expressing tumors
WO2009009523A2 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
KR20110013391A (ko) 2008-04-11 2011-02-09 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Ｃｄ37 면역치료제 및 이작용성 화학치료제와 이의 병용물
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
MX339621B (es) 2010-04-13 2016-06-02 Celldex Therapeutics Inc * Anticuerpos que se unen a cd27 humano y uso de los mismos.
US9249226B2 (en) 2010-06-09 2016-02-02 Genmab A/S Antibodies against human CD38
CA2853138A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
KR102597989B1 (ko) 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
KR102649222B1 (ko) 2015-05-20 2024-03-18 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
CN113603782A (zh) 2015-05-29 2021-11-05 艾伯维公司 抗cd40抗体及其用途
CA2990406A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MY193078A (en) 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
IL312251A (en) 2015-10-02 2024-06-01 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MY202415A (en) 2015-11-03 2024-04-27 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340921A (en) * 1986-07-03 1994-08-23 T Cell Sciences, Inc. Γ, δT cell receptor and methods and detection

Also Published As

Publication number Publication date
EP0330191B1 (en) 1996-10-02
DE68927277T2 (de) 1997-03-20
WO1989008114A1 (en) 1989-09-08
AU2947389A (en) 1989-09-22
EP0330191A2 (en) 1989-08-30
DE68929329D1 (de) 2001-10-31
EP0739980A3 (en) 1996-12-18
DE68929329T2 (de) 2002-07-04
ES2164794T3 (es) 2002-03-01
EP0739980A2 (en) 1996-10-30
ATE206161T1 (de) 2001-10-15
ATE143690T1 (de) 1996-10-15
EP0739980B1 (en) 2001-09-26
DE68927277D1 (de) 1996-11-07
HUT53672A (en) 1990-11-28
AU627710B2 (en) 1992-09-03
HU890958D0 (en) 1990-09-28
EP0330191A3 (en) 1990-08-16

Similar Documents

Publication Publication Date Title
ES2094113T3 (es) Dna que codifica cd40.
FI883722A (fi) Alfa-amiderande enzymkompositioner och foerfaranden foer deras framstaellning och anvaendning.
IL90423A (en) Interleukin-1 inhibitors methods for producing them pharmaceutical compositions containing them isolated DNA sequences encoding interleukin-1 inhibitors and host cells and vectors containing them
DE69637631D1 (de) Künstliche säuger chromosome
DE3380958D1 (de) Beta-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE3775618D1 (de) Verfahren zur herstellung von toner durch suspensionspolymerisation.
PL308742A1 (en) Method of recombining and host cell for producing xylythol
DE3683447D1 (de) Verfahren zur herstellung von humanlysozym.
DE69403210D1 (de) Verfahren zur herstellung von n-acetylneuraminsäure
AU5559499A (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
DE69430975D1 (de) Verfahren zur Herstellung von Proteinen
ATE118817T1 (de) Verfahren zur herstellung von xbai- restriktionsendonuklease und -methylase.
ATE40370T1 (de) Phenylengruppen-haltige organosilane, verfahren zu ihrer herstellung.
EP0776972A4 (en) GENE ENCODING THE IgG-Fc-BINDING PROTEIN
KR890001942A (ko) (±)-시스 또는 (±)-트란스-퍼메트르산의 광학 분할법
DE58904756D1 (de) Verfahren zur herstellung von tert.-amylalkohol (taa).
DE3667960D1 (de) Verfahren zur herstellung von halogen-magnesium-alanat und dessen verwendung.
EP0293079A3 (en) Chlamydia vaccine
DE68910702D1 (de) Verfahren zur Herstellung von Silikongelsphären.
UA27771C2 (uk) Електролітична комірка (варіанти) та спосіб мічення протеїнів, пептидів і інших органічних молекул
DE68916022D1 (de) Verfahren zur herstellung von wasserstoffgas.
DE3869885D1 (de) Verfahren zur herstellung des gereinigten naphthalin-2,6-dicarbonsaeure-bis (2-hydroxyethyl)-esters.
EP0342422A3 (en) Process for the preparation of 2',3'-dideoxynucleosides, and intermediates used therein
DE3875091D1 (de) Verfahren zur herstellung von cyanwasserstoff.
DE3677254D1 (de) Verfahren zur herstellung von 1,3-di(alkoxicarbonylamino)propanen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 330191

Country of ref document: ES